When can we expect apotex's ruxolitinib to be fda approved?

Current Status of Apotex's Ruxolitinib FDA Approval

Apotex has been working on an abbreviated new drug application (ANDA) for ruxolitinib, a medication used to treat myelofibrosis and polycythemia vera [1]. To date, there is no specific timeline announced by the FDA for the approval of Apotex's ruxolitinib.

Comparison to Existing Brands

Currently, ruxolitinib is only available under the brand name Jakafi, manufactured by Incyte Corporation, which holds the New Drug Application (NDA) approval from the FDA. The patent for Jakafi is expected to expire in 2033 [2], which could potentially allow Apotex's generic version to enter the market after that date.

Patent Challenges and Exclusivity

As the expiration date for the Jakafi patent approaches, it is likely that Apotex's ANDA will receive attention from the FDA. However, there could be patent challenges from Incyte Corporation to maintain their exclusivity on the market. This could lead to delays in Apotex's generic version being approved by the FDA.

Timeline for Approval

While there is currently no specific timeline for Apotex's ruxolitinib to be FDA-approved, the expiration of the patent for Jakafi in 2033 may provide an opportunity for Apotex's generic version to enter the market. Until then, the exact timeline for approval remains uncertain.

Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com